CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Gastrobase.it
Mediexplorer.it

Search results for "Dronedarone"

The FDA ( Food and Drug Administration ) has completed a safety review of Multaq ( Dronedarone ). This review showed that Multaq increased the risk of serious cardiovascular events, including death, w ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Pradaxa ( Dabigat ...


Gilead Sciences has announced results from HARMONY, a randomized, double-blind, placebo-controlled phase 2 study evaluating the effect of Ranolazine and low-dose Dronedarone, each given alone and in c ...


Before initiating antiarrhythmic drug therapy, treatment of precipitating or reversible causes of atrial fibrillation is recommended. ( Class I; Level of Evidence: C ) The following antiarrhythmic ...


Atrial fibrillation is the most frequent sustained arrhythmia. Atrial fibrillation recurs frequently after restoration of normal sinus rhythm. Antiarrhythmic drugs have been widely used to prevent rec ...


Dronedarone ( Multaq ) is a non-iodinated benzofuran derivative with antiarrhythmic properties. In placebo-controlled atrial fibrillation ( AF ) trials, the drug was found to have divergent effects on ...


Dronedarone ( Multaq ) is an Amiodarone analog that differs structurally from Amiodarone in that the iodine moiety was removed and a methane-sulfonyl group was added. These modifications reduce thyr ...


The aim of a study was to examine mortality and liver disease among patients exposed to Dronedarone ( Multaq ).There has been concern about the safety of Dronedarone, especially for patients with hear ...


Dronedarone ( Multaq ) is a new antiarrhythmic drug used in the treatment of atrial fibrillation ( AF ). Researchers at Feinberg School of Medicine, Northwestern University ( Chicago, USA ) have inves ...


A study has assessed safety and cardiovascular outcomes of Dronedarone ( Multaq ) in patients with paroxysmal or persistent atrial fibrillation ( AF ) with coronary heart disease ( CHD ). Coronary h ...


Edoxaban ( Lixiana ), an oral direct factor Xa inhibitor, is in development for thromboprophylaxis, including prevention of stroke and systemic embolism in patients with atrial fibrillation. P-glyco ...


Dronedarone ( Multaq ) is a non-iodinated benzofuran derivative with antiarrhythmic properties. In placebo-controlled atrial fibrillation trials, the drug was found to have divergent effects on endpoi ...


Elevated serum Digoxin concentration can cause toxicity, including death. Dronedarone ( Multaq ) increases Digoxin concentration by P-glycoprotein interaction. In PALLAS ( Permanent Atrial Fibrillat ...


Little is known in clinical practice about antiarrhythmic drugs ( AADs ) use in patients with atrial fibrillation ( particularly younger ones ) who do not have structural heart disease. Using the ...


Dronedarone ( Multaq ) is a benzofuran derivative with a pharmacological profile similar to Amiodarone but has a more rapid onset of action and a much shorter half-life ( 13-19 h ). Researchers ha ...